EWTX · Edgewise Therapeutics, Inc.
Market Cap
$4.60B
Shares
108.60M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$41.77
Open$42.24
Day$40.64–42.46
52W close$13.70–48.35
Avg vol 30d1.2M
Short int9.7M · 8.9% float · 6.4d
Short vol60%
Last earningsMay 13, 2024
DataMar 2021–Aug 2026
Filing10-Q · Aug 6
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 6, 2026
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Very Strong
Sentiment
Bullish
Fundamentals
Poor
Quant / Vol
Very High
Market backdrop
VIX 16.3 · calm
Equity put/call 0.70
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+28%
above
Price vs 50-day avg
−1%
below
RSI (14)
46
neutral
MACD trend
Negative
52-week position
81%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+9%
trailing
6-month return
+43%
trailing
YTD return
+68%
this year
Relative strength
+29%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $42 › 200d $33 — 50d above 200d
Institutional flow
Accumulating
+5% holders QoQ · +41 funds added
Insider flow
Distributing
Net -$785.0K over 90 days · 100% sells
Short interest
Falling
8.91% of float · ▼ -1.6% MoM · 6.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
227 holders — near 3-yr high, broad support
Squeeze score
61
elevated · 0–100
Fundamentals
EPS growth
−12%
Y/Y
Free cash flow
$-144.1M
Quant / Vol
risk profile
Volatility
78%
annualized · 1-yr
Max drawdown
−21%
past year
ATR
5.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+28%
Bullish
Price vs 50-day avg
−1%
Neutral
RSI (14)
46
Neutral
MACD trend
Negative
Bearish
52-week position
81%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $42 › 200d $33 — 50d above 200d
Institutional flow
Accumulating
+5% holders QoQ · +41 funds added
Insider flow
Distributing
Net -$785.0K over 90 days · 100% sells
Short interest
Falling
8.91% of float · ▼ -1.6% MoM · 6.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
227 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $14
Now $42 · 81%
Range high $48
vs 200-day avg +28%
vs 50-day avg -1%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
EWTX
this stock
Edgewise Therapeutics, Inc.
|
$4.60B | +68.3% | — | — | 8.9% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$137.30B | +20.1% | +46.2% | 31.6 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.77B | +3.5% | +20.8% | 19.7 | 2.3% |
|
ARGX
Argenx SE
|
$64.16B | +22.3% | — | — | 1.9% |
|
CSLLY
Csl Ltd
|
$59.51B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| EWTX | -6.6% | +8.8% | +42.6% | +8.7% | +68.3% |
| SPY | +0.5% | +1.2% | +13.3% | +2.7% | +12.5% |
| vs SPY | -7.1% | +7.6% | +29.3% | +6.0% | +55.9% |
Key facts
CIK
1710072
CUSIP
28036F105
13F (30d)
197 filings
193 filers
Visit website
Investor relations